Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (NYSE:ZOM)’s share price shot up 15.8% on Wednesday . The stock traded as high as $0.46 and last traded at $0.44, 162,100 shares were traded during mid-day trading. A decline of 32% from the average session volume of 239,714 shares. The stock had previously closed at $0.38.

Separately, HC Wainwright restated a “buy” rating on shares of Zomedica Pharmaceuticals Corp (NYSEAMERICAN) in a research note on Wednesday, June 5th.

The company has a market cap of $46.92 million, a price-to-earnings ratio of -2.44 and a beta of 0.23. The firm has a 50-day moving average price of $0.31 and a 200 day moving average price of $0.38.

Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (NYSE:ZOM) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.02) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.06) by $0.04. As a group, sell-side analysts expect that Zomedica Pharmaceuticals Corp will post -0.16 EPS for the current year.

A number of institutional investors have recently added to or reduced their stakes in ZOM. Morgan Stanley increased its stake in Zomedica Pharmaceuticals Corp (NYSEAMERICAN) by 1,523.2% during the second quarter. Morgan Stanley now owns 111,598 shares of the company’s stock valued at $25,000 after purchasing an additional 104,723 shares during the last quarter. Paloma Partners Management Co acquired a new stake in shares of Zomedica Pharmaceuticals Corp (NYSEAMERICAN) during the second quarter worth $45,000. Vanguard Group Inc. lifted its position in shares of Zomedica Pharmaceuticals Corp (NYSEAMERICAN) by 139.1% in the 2nd quarter. Vanguard Group Inc. now owns 383,154 shares of the company’s stock worth $88,000 after buying an additional 222,920 shares during the last quarter. Finally, Geode Capital Management LLC lifted its position in shares of Zomedica Pharmaceuticals Corp (NYSEAMERICAN) by 13.3% in the 4th quarter. Geode Capital Management LLC now owns 136,655 shares of the company’s stock worth $168,000 after buying an additional 16,065 shares during the last quarter. 13.06% of the stock is owned by hedge funds and other institutional investors.

About Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (NYSE:ZOM)

Zomedica Pharmaceuticals Corp., a development stage veterinary diagnostic and pharmaceutical company, engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. The company's lead drug product candidate is ZM-012, a tablet formulation of metronidazole targeting the treatment of acute diarrhea in dogs.

Featured Article: Why do companies issue monthly dividends?

Receive News & Ratings for Zomedica Pharmaceuticals Corp (NYSEAMERICAN) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zomedica Pharmaceuticals Corp (NYSEAMERICAN) and related companies with MarketBeat.com's FREE daily email newsletter.